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High-contrast grating resonators 
for label-free detection of disease 
biomarkers
Tianbo Sun1,*, Shu Kan2,*, Gerard Marriott2 & Connie Chang-Hasnain1
A label-free optical biosensor is described that employs a silicon-based high-contrast grating (HCG) 
resonator with a spectral linewidth of ~500 pm that is sensitive to ligand-induced changes in surface 
properties. The device is used to generate thermodynamic and kinetic data on surface-attached 
antibodies with their respective antigens. The device can detect serum cardiac troponin I, a biomarker 
of cardiac disease to 100 pg/ml within 4 mins, which is faster, and as sensitive as current enzyme-linked 
immuno-assays for cTnI.
Point of care devices (POC) offer advantages over conventional technologies for biomarker detection including 
cost and speed, while requiring smaller amounts of sample and reagents. Since diagnostic tests account for an 
appreciable percentage of the national healthcare budget, the demand for more cost-effective POC devices and 
decentralized strategies for disease diagnostics will inevitably increase1–14.
In most cases, the amount of a target biomarker associated with a specific cancer, or neurologic or cardio-
vascular disease, is recorded within a POC device using an enzyme-linked immuno-assay (ELISA). The optical 
read-out may be as simple as a change in the absorption of light or the intensity of fluorescence of a dye that 
is produced by the antibody-linked enzyme2,3. Enzyme-antibody conjugates are produced by random chemi-
cal crosslinking of antibody and enzyme molecules, which produces a heterogeneous population of conjugates, 
some of which will exhibit a reduced affinity for the target biomarker. Moreover, a typical ELISA assay involves 
time-consuming incubation and wash-steps requiring fluidic control that increases the complexity and cost of the 
device. While ELISA-based detection dominates the field of POC devices, recent studies have shown label-free 
detection modalities offer an attractive alternative7–13. In particular, label-free optical sensing techniques have 
been described for POC devices including those that detect specific biomarkers using surface plasmon reso-
nance7,8, photonic crystals9,10, integrated micro-cavities11,12, and metal nanohole arrays13. Although these devices 
allow for sensitive detection of target biomarkers, they are produced by expensive e-beam lithography and have 
limited utility for remote testing owing to the need for exact optical alignments that are usually carried out by 
specialized technicians.
Here we describe a new type of POC device that integrates a high-contrast grating (HCG) resonator for 
label-free detection of target biomarkers (Fig. 1(a,b))15,16. The high-contrast grating structure is shown to generate 
with very high efficiency, specific and strong resonances that are sensitive to changes in surface properties and can 
be monitored using surface-normal excitation15. The resonance quality factor (defined as resonance wavelength 
divided by the full width half maxima) of these devices is reported at ~3000 and has a refractive index sensitivity 
~418 nm/RIU, both of which are higher than those reported for other nanostructure devices that also use direct 
surface-normal coupling10–13, including the guided-mode resonant filter10 and metal nanohole arrays13.
The binding of a biomolecule to the HCG surface results in a red-shift of the resonance wavelength, which is 
a consequence of the effective increase in the length of the optical cavity (Fig. 1(c)). A tunable laser is used as the 
excitation source and the reflected signal is recorded using a photodiode over a wavelength range of interest. The 
data is subsequently transferred to a computer for further processing (see Method). The HCG resonator has a 
narrow linewidth (0.5 nm) and exhibits a high sensitivity to changes in surface-binding, with even small changes 
in surface properties generating noticeable shifts in the resonance wavelength. The surface normal input of the 
probe light beam simplifies the optical alignment of the device, and allows us to use a low cost tunable laser and 
photodiode to measure molecular events at the surface. HCG’s are produced en masse, and at low cost using a 
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standard silicon optical lithography and etching technique (see Method) that can accommodate 96-well, 384-well 
or 1536-well formats that may be suitable for high-throughput screening applications.
The HCG device exhibits a remarkable sensitivity to surface-binding events. This feature is exploited 
for the detection of biomarkers some of which are associated with human disease. This is achieved in part by 
chemically-linking detection antibodies against specific biomarkers to the HCG surface where they provide a 
platform for rapid, sensitive and specific detection of disease-associated antigens17. We are particularly interested 
in using the HCG device for label-free analysis of troponin I (cTnI), which is released into the blood from dam-
aged cardiac muscle cells after myocardial infarction. cTnI in serum is a reliable and validated clinical marker of 
cardiac muscle tissue injury and stroke, which affects ~1 million people in the USA each year18–21. cTnI is often 
detected from blood samples using ELISA based platforms with read-out times of that can be as long as 10-hours. 
In this study we show how a HCG platform is used to generate quantitative analysis of cTnI over a clinically rele-
vant concentration range of 100 pg/ml to 80 μg/ml17 within 4 minutes.
Results
Design, fabrication and characterization of HCG resonators. The HCG is formed from an ultra-thin 
layer (a few hundred nm) of a silicon grating surrounded by a material of low refractive index. A schematic of a 
Si-based HCG resonator with surface-normal optical coupling is shown in Fig. 1(a). Unlike other gratings, the 
refractive index contrast in the HCG is high at both the entrance and exit planes. The large difference in refractive 
index (contrast) between the grating plane and its surroundings results in strong coupling between resonance 
modes at both the exit and entrance boundaries. Resonance is established inside the grating layer with the air/Si 
and Si/oxide interfaces acting as cavity boundaries. By choosing an appropriate grating period and grating band-
width, the HCG is able to support only two resonance modes16. Moreover, by using a grating layer of appropriate 
thickness, the two resonance modes can be made to interfere constructively at the entrance and exit boundaries. 
This feature results in a high-Q resonator with the light propagating in a direction that is normal to the grating 
plane. This phenomenon has been described in earlier publications15,16; a brief summary of this principle is pre-
sented herein. We define ρ as the coupling coefficient matrix between the resonance modes at the entrance/exit 
boundaries, ϕ as the propagation factor inside the Si grating layer and C as the vector representing a self-sustain-
able mode that satisfies the round-trip condition. We can show that:
ρϕρϕ= .C C (1)
The intrinsic quality factor of HCG resonance is calculated by
Figure 1. HCG resonator as a label-free biosensing platform. (a) Schematic of a surface normal coupled 
HCG resonator. (b) SEM image of gratings within a single fabricated HCG resonator. (c) Schematic of the 
principle of using HCG resonator as a protein binding sensing platform. The red-dashed curve indicates a 
red-shift in the resonance wavelength occurs when a protein binds to HCG surface. (d) A single mode fiber 
probe is immersed in the fluid above the HCG surface to avoid surface reflections. (e) A reflection spectrum 
recorded for a device having the configuration schematized in (d). A tunable laser centered at 1550 nm is used 
as excitation source and is run in a continuous sweeping mode. The reflection power is recorded in real time and 
is synchronized to laser sweeping rate.
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where tg is the grating thickness, λ is the wavelength of the incident light, ng is the group index, and r represents 
the eigenvalues of matrix ρϕ16.
A detailed analysis of the design algorithm for the HCG resonator is described in Sections 1 & 4 of ref. 16. For 
HCG devices used in this study, the grating period is 792 nm, the bandwidth is 427 nm, and the grating thickness 
is 500 nm. An SEM image of gratings within a single device is shown in Fig. 1(b), with the measured dimension 
agreeing well with design value, as well as verifying the accuracy of our fabrication process.
A single mode fiber is used to excite resonances inside the HCG resonator. In practice, the fiber is adjusted 
vertically above the surface of the HCG to excite resonance – we show that this simple optical alignment results 
in accurate and robust measurement of reflection spectrum (Fig. 1(d). The fiber tip is immerged inside a target 
solution to avoid reflection at the surface. The reflection spectrum under fiber illumination of a HCG device 
immersed in phosphate buffered saline (PBS) is recorded as described in the Methods section, with a typical 
recording shown in Fig. 1(e). The quality factor determined from the reflection spectrum data shown in Fig. 1(e) 
is ~3000 with a center wavelength of 1564 nm.
The HCG resonator has several advantages over other on-chip resonance-based devices for the detection 
of molecular events including an intrinsic ability to establish unique patterns of resonance modes. A simulated 
mode pattern at resonance for an HCG resonator excited with a Gaussian beam of ~10 μm spot size (output from 
a single mode fiber) is shown in Fig. 2(a). The top view of the resonance (at 1564 nm) sliced through the center 
of resonator is shown in Fig. 2(a). Efficient optical coupling of the input light to the HCG device is facilitated 
by the large mode overlap between the input Gaussian beam and the resonance mode. The actual sensing area 
is determined by the size of resonance pattern, and in our studies (illumination using a single mode fiber) it is 
approximately 40 μm2. The side view of the resonance inside one grating period of the HCG is shown in Fig. 2(b), 
which reveals a key design feature in that the mode has a strong intensity at HCG surface. This feature results in 
strong interactions between the resonant light and surface-attached biomolecules.
Sensitivity of the HCG device to changes in refractive index. Next we carried out quantitative meas-
urements on the intrinsic sensitivity of the HCG device to changes in refractive index. First we immersed the 
sensor surface with a liquid of known refractive index (RI), using solvents with a RI range from 1.494 to 1.506. 
The results of these measurements, shown in Fig. 3(a), show that an increase in RI results in a red-shift of the res-
onance wavelength. The shift in wavelength as a function of the change in RI, plotted in Fig. 3(b), reveals a linear 
relationship between Δ RI and the shift in the resonance wavelength. HCG sensors reported in this study have 
a RI sensitivity (RIS) of 418 nm/RIU (Refractive Index Unit), which is higher than corresponding sensitivities 
reported for other dielectric structures9,10. The high sensitivity of the HCG is attributed to the special resonance 
mode pattern of the HCG resonator.
Quantitative analysis of antibody-antigen interactions using HCG sensors. To characterize 
the sensitivity of the HCG sensor in detecting target antigens, we tested a complementary antibody-antigen 
Figure 2. HCG resonator intensity pattern at resonance wavelength. (a) Top view of the resonance inside the 
HCG cavity excited by Gaussian beam with a 10 μm spot size at resonance wavelength (1564 nm). A large mode 
overlap with the input beam contributes to a simple and efficient coupling of the input light. (b) Side view of the 
resonance (showing one period) inside the HCG cavity. The resonance is designed to have large mode exposure 
to surroundings, which contributes to the high sensitivity of the device.
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pair composed of unlabeled IgG from rabbit serum (Sigma, I5006) as the antigen, and a polyclonal antibody 
directed against rabbit IgG that was produced in goat (Sigma; R2004) as the detection antibody. A schematic of 
the antibody-antigen binding platform is shown in Fig. 4(a,b). First the surface of the HCG sensor is coupled 
covalently with the anti-rabbit IgG antibody via a maleimide-thiol coupling reaction (see Methods). The spectral 
response of the sensor is recorded before adding rabbit IgG, with the resonance wavelength for the measurement 
assigned as the reference. Next solutions (200 μl) of the rabbit IgG (antigen) are added separately and sequentially 
Figure 3. Quantification of HCG sensor sensitivity at different refractive indices. (a) Reflection spectra for a 
HCG resonator immersed in liquids with different refractive indices ranging from 1.494 to 1.506. (b) Resonance 
wavelength as function of the change in refractive index.
Figure 4. Three-dimensional schematic (not drawn to scale) and the experimental measurements illustrate 
the detection scheme using HCG resonator as platform for antibody-antigen binding assay. (a) HCG sensor 
immobilized with capturing antibody. (b) Antigen attaches to the antibody immobilized sensor and changes the 
surface properties of HCG sensor. (c) Real time recording of the interaction between surface bound goat anti-
rabbit IgG and different concentrations of antigen (rabbit IgG). The dashed lines are the corresponding fits to 
data. (d) Red dots show the resonance wavelength shift for different concentrations of purified rabbit IgG added 
to a HCG resonator surface-coated with anti-rabbit IgG. The red dashed line is the fit to recorded data. Blue 
dots show that the incubation of mouse IgG with surface linked anti-rabbit IgG results in smaller shift of the 
resonance wavelength. The black triangles show the response of the HCG sensor to the addition of rabbit IgG 
dissolved in goat serum (Sigma). The bars indicate the error range for the 3 measurements.
www.nature.com/scientificreports/
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to the HCG surface over a concentration range from 0.1 ng/ml to 1 mg/ml. The reflection spectrum is recorded 
after the addition of each antigen sample.
Spectral data showing an interaction between surface-bound goat anti-rabbit IgG and rabbit IgG studies are 
presented in Fig. 4(c,d). A standard curve for the device is generated by recording the spectral shift for different 
concentrations of the purified antigen in PBS; three parallel titrations are performed for each antigen concen-
tration to improve the precision of the measurement. The standard curve, recorded over a 1000-fold range of 
antigen concentration, shows the red-shift in the resonance wavelength is proportional to the concentration of 
antigen. The signal associated with antigen binding to the surface-coupled antibody saturates at ~3 μg/ml. We 
established the lowest detectable concentration of antigen recorded for this device at 100 pg/ml, which resulted in 
a red-shift of the resonance wavelength of 60 pm (red trace of Fig. 4(d)). The specificity of the interaction between 
complementary antibody-antigens is demonstrated using a negative control composed of a non-complementary 
antibody-antigen pair, with data for surface bound anti-rabbit IgG and mouse IgG shown in the blue line of 
Fig. 4(d). The shift in the wavelength for this control sample is at least three times smaller compared to the com-
plementary rabbit IgG/anti-rabbit IgG system. The device worked equally well for the complementary rabbit 
IgG/anti-rabbit IgG pair where the rabbit IgG was dissolved in serum rather than PBS, which suggests that a 
low level of non-specific binding of serum proteins to the HCG surface. Three known concentrations of rabbit 
IgG dissolved in serum (2 ng/ml, 10 ng/ml and 80 ng/ml) lie close to their expected values on the standard curve 
(black triangles in Fig. 4(d)).
To demonstrate the ability of the HCG device to record dynamic interactions between rabbit IgG and 
anti-rabbit IgG, we recorded the time-dependence of the shift in the resonance wavelength after adding rabbit 
IgG to the anti-rabbit IgG labeled surface. Figure 4(c) shows the normalized surface binding curves as function 
of time, which were obtained by integrating the difference of the spectral response (shift of resonance wave-
length) for the started time and that recorded at a given time. In this study the surface binding response of the 
HCG device was recorded continuously after the addition of 4 different concentrations of the antigen. As shown 
in Fig. 4(c), the signal associated with antigen binding increases exponentially with a time constant of ~50 sec 
(on average), and reaches a plateau at 95% of the equilibrium value within 200 seconds. In conclusion, we have 
shown the HCG device allows for rapid (within 4 minutes) and quantitative analyses of the amount of a target 
antigen in buffer and serum, and shown the device can also calculate kinetic constants associated with complex 
formation (or dissociation).
Quantitative analysis of cardiac Troponin I. Purified human cTnI19 is detected in serum and PBS using 
a commercial anti-human troponin I antibody that binds to an epitope between residues 86–209 on troponin I 
(sc-133117, Santa Cruz Biotechnology). The monoclonal antibody is covalently linked to the HCG surface using 
the maleimide-thiol coupling strategy described in the Methods section. The standard curve for cTnI binding to 
anti-cTnI on the HCG surface is generated by measuring the change in the resonance wavelength for different 
dilutions of purified cTnI in PBS (0.1 ng/ml to 80 μg/ml; Fig. 5(a)). Purified cTnI is also measured on the HCG 
Figure 5. (a) Measurement results for troponin I molecule inside PBS (red dots) and serum (black triangles). 
The bars indicate the error range over 3 measurements. (b) HCG sensor array combined with fiber array for 
high throughput screening.
www.nature.com/scientificreports/
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device after being diluted at 4 defined concentrations in fetal bovine serum. The concentrations of cTnI in these 
serum samples are determined by comparing their spectral shifts to a standard curve (black triangles in Fig. 5(a)). 
Our studies show the HCG device is useful for rapid (4 minutes) and quantitative determinations of cTnI in PBS 
and in mock serum samples over a concentration range that is relevant for clinical analysis of cTnI in the serum 
of stroke victims (100 pg/ml to 80 μg/ml)17.
Discussion
Devices and detection systems that allow for quantitative, sensitive and accurate determinations of validated bio-
markers at levels associated with early detection of a disease are highly valued in clinical diagnoses. The most pop-
ular approach to quantify specific biomarker in POC devices is based on the ELISA. ELISA platforms however are 
slow, and require complex fluidic control for multi-step processing of the sample and detection reagents, the time 
to complete an ELISA assay is usually on the order of 4–12 hours22. Moreover, ELISAs employ at least two coupled 
antibodies, the capture antibody mobilized on the microwell surface and a detection antibody that is conjugated 
with a florescent dye or an enzyme that chemically transforms a substrate into a colored or chemiluminescent 
product for readout, the performance of which vary for particular manufacturers and in different batches22,23. In 
this study we described a high-contrast grating (HCG) resonator that allows for label-free detection and quantifi-
cation of interactions between only one surface bound antibody and its target antigen, shorten the running time 
to 4 minutes, at the same time achieving comparable detection limits (100 pg/ml) to reported commercial ELISA 
kits and the theoretical detection limit of a HRP/TMB-based ELISA assay24. We also provide a performance com-
parison between the HCG sensor and other reported label free sensor technologies in Table 1. The HCG device 
compares favorably with other technologies that have been applied to the detection of biomarkers such as cTnI 
in terms of detection sensitivity (100 pg/ml to 80 μg/ml)17 and sensing area. Moreover, we have shown the HCG 
device is relatively insensitive to the non-specific binding of serum proteins, which is a critical requirement in 
the development of clinically relevant assays of disease biomarkers. Moreover the HCG device offers additional 
benefits that include speed, with assays typically complete within 4 minutes), feasibility of mass production, Si 
CMOS compatibility, and suitability for remote detection eg in the home or in a doctor’s office. The low-cost 
HCG device is simple to construct and to operate, and allows for sensitive and robust, surface-based detection 
formats to quantify disease biomarkers at disease-relevant concentrations within 4 minutes. We further showed 
that cTnI can be detected in mock serum samples with a sensitivity of 100 pg/ml, which is sensitive enough for 
the detection of serum cTnI levels associated with acute myocardial infarction (AMI), and compares well with the 
sensitivity obtained using POC devices (> 400 pg/ml)17,25. The simple design of the HCG sensor, which is based 
on a standard silicon manufacturing process, allows for the fabrication of more than 10000 unique sensors on 
a single cm2 chip that can be further embellished with integrated microfluidic and electronic systems. The inte-
gration of a stand-alone tunable laser and photodiode helps to reduce the cost of the measurement system, while 
the surface-normal fiber detection format overcomes a requirement in other competing devices for continuous 
adjustments to maintain a precise optical alignment. A simple extension of the HCG platform described in this 
study would be to combine a HCG sensor array with a fiber array, as shown in Fig. 5(b). This new platform could 
facilitate high-throughput, parallel screening of biomarkers in thousands of samples.
Methods
Fabrication method. The devices are patterned onto a 6 inch silicon-on-insulator with Si-layer thickness 
500 nm wafer (from SOITEC) using DUV (ASML 300) lithography followed by silicon refractive ion etching 
(Lam Research), which are both standard processes in semiconductor manufacturing.
Reflection spectrum measurements. A tunable laser (HP 8164) centered at 1550 nm is used as the 
excitation and is set in a continuous sweeping mode between 1560 nm and 1565 nm at a rate of 40 nm/sec. The 
power of the reflected light is recorded using a photodiode in real time and is synchronized to the laser sweep rate 
through an Oscilloscope. Data is then transferred into a computer for further process.
Device Sample
Sensitivity 
[pg/ml]
Sensing 
Area 
[μm2] Manufacturing Test Specification
SPR8 IgG 40 ~105 Not Si compatible Prism coupler
Au nanoparticle7 BSA 4 ~1 Not Si compatible; Nonuniformity Low detection efficiency
CNT5 IgG 1 ~6 Low yield Fragile
Nanolaser10 BSA 17 < 1 Not Si compatible; E-beam required High NA optics
Si ring resonator11 BSA 104 ~60
Si CMOS 
compatible; 
Optical Litho.
Angled Fiber 
I/O + grating coupler
HCG resonator IgG 100 ~40
Si CMOS 
compatible; 
Optical Litho.
Surface normal Fiber I/O 
with high efficiency
Table 1. Comparison of label-free biosensor in biomarker detection10.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:27482 | DOI: 10.1038/srep27482
Antibody immobilization. Maleimide groups are introduced to the antibody by treating the antibody 
(1 mg/ml) with 100 μM maleimidobenzoic acid succinimide ester (MBS, Sigma) in PBS for 2 hours at room tem-
perature. The mixture is then passed over a PD-10 column in PBS to remove unlabeled MBS and fractions con-
taining the MBS-antibody conjugate are pooled. The surface of the Si-sensor is thiol-silanized using a fresh 5% 
solution of (3-Mercaptopropyl) trimethoxysilane (MPTMS) in IPA for 1 hr. After washing with PBS the surface 
is treated with a 1mg/ml of the MBS-antibody. The reaction between the MBS-antibody conjugate and surface 
thiol groups on the HCG results in a stable thioether bond. After an incubation period of two hours, the surface 
is washed with PBS, and a blocking buffer containing 3%BSA is applied to the surface to reduce the non-specific 
binding of serum proteins.
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